Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586879 | 1.00 | MAPT (0.40) | MAPTALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL5611077 | 1.00 | MAPT (0.40) | MAPTALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL5611040 | 0.89 | MAPT (0.34) | MAPTALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL14586878 | 0.89 | MAPT (0.34) | MAPTALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL5611082 | 0.77 | NPC1 (0.42) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL5611084 | 0.77 | NPC1 (0.42) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL14586877 | 0.77 | NPC1 (0.42) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL14586883 | 0.76 | KDM4E (0.47) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL14586881 | 0.75 | CTSK (0.41) | MAPTALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL14586918 | 0.75 | ALDH1A1 (0.38) | MAPTALDH1A1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183302-B2 | Iminothiazolidinones as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050096364-A1 | Iminothiazolidinones as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
| US-20050069522-A1 | Combination pharmaceutical agents as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | disclosed |
| WO-2004014852-A2 | IMINOTHIAZOLIDINONES AS INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014313-A2 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050069522-A1 | Combination pharmaceutical agents as inhibitors of HCV replication | IMPDH1, IMPDH2, IMPA1 | MAPT 4776/4885ALDH1A1 399/4885SMN1; SMN2 4473/4885 |
| US-20050096364-A1 | Iminothiazolidinones as inhibitors of HCV replication | EIF2AK2, RTF2, IFNAR1 | MAPT 3563/4885ALDH1A1 1462/4885SMN1; SMN2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.